Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mixed Sugar Electrolyte Injection is a parenteral nutrition and fluid replacement solution developed by Beijing Minkan Baicao Pharmaceutical Technology. It is a combination product typically composed of three carbohydrates—glucose, fructose, and xylitol—along with essential electrolytes including sodium, potassium, magnesium, and chloride. This formulation is designed to provide a balanced energy source and maintain electrolyte homeostasis in patients who are unable to receive adequate nutrition orally or enterally, such as those in post-operative recovery or intensive care. The inclusion of fructose and xylitol allows for insulin-independent energy utilization, which is particularly beneficial in managing patients with stress-induced hyperglycemia or glucose intolerance, as these sugars are metabolized through pathways that do not require insulin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mixed sugar electrolyte injection.